Stockscreener 앱 받기
7.33
0.27%
-0.02
시장 영업 전:
7.02
-0.31
-4.23%
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target - Investing.com India
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k - Yahoo Finance
EyePoint Pharmaceuticals: Q4 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highli - GuruFocus.com
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance
EyePoint Pharmaceuticals Reports 2024 Financial Results - TipRanks
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss - Investing.com India
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals Q4 2024 Earnings: Revenue Beats at $11. - GuruFocus.com
EYEPOINT PHARMACEUTICALS Earnings Results: $EYPT Reports Quarterly Earnings - Nasdaq
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat - Investing.com
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Pharmaceuticals, Inc. Q4 Loss Increases, Misses Estimates - Nasdaq
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns? - StockTitan
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result - Yahoo Finance
Eyepoint Announces Participation At Upcoming Investor Conferences - MENAFN.COM
EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Nasdaq
How to Watch EyePoint's March Presentations at Two Major Healthcare Investment Conferences - StockTitan
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Brokerages - Defense World
EyePoint Pharmaceuticals (EYPT) Projected to Post Earnings on Wednesday - MarketBeat
(EYPT) Technical Pivots with Risk Controls - Stock Traders Daily
EyePoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on Thursday - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - Simply Wall St
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 - The Manila Times
When Will EyePoint Reveal Its 2024 Performance? Key Date for Retinal Disease Innovator - StockTitan
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - The Manila Times
Will EyePoint's New Clinical Data Reveal Breakthrough in Macular Degeneration Treatment? - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 13.6%Still a Buy? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Adversity is less terrifying than hope: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Grants Stock Options to New Employees as Inducement Awards - Nasdaq
EyePoint Grants Strategic Stock Options Worth $136,500 to Key New Hires - StockTitan
(EYPT) Trading Advice - Stock Traders Daily
230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by abrdn plc - MarketBeat
TD Cowen maintains EyePoint stock Buy rating, $20 target - MSN
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from Chardan Capital - MarketBeat
3.70%
자본화:
|
볼륨(24시간):